10-Q: Nutra Pharma Faces Liquidity Crisis Amidst Revenue Decline

Nutra Pharma Corp. reported a significant net loss and declining revenues for Q1 2024, raising substantial doubt about its ability to continue as a going concern.

Summary

• Net sales to unrelated customers decreased by 30.79% to $37,732 for the three months ended March 31, 2024, compared to $54,522 in the prior year.
• Net sales to related party Avini Health plummeted by 65.23% to $34,949, down from $100,502, as Avini began manufacturing its own products.
• Gross profit declined to $35,197 (48.4% margin) for Q1 2024, from $103,099 (66.5% margin) in Q1 2023, partly due to a $15,000 reserve for supplier advances.
• Operating expenses decreased by 16.61% to $330,506, primarily due to lower professional fees and no bad debt expense from a related party in Q1 2024 (compared to $105,465 in Q1 2023).
• Net loss improved by 27.95% to $(426,934) for Q1 2024, compared to $(592,560) in Q1 2023.
• The company reported an accumulated deficit of $75,372,408, a working capital deficit of $14,278,846, and a stockholders' deficit of $14,191,742 as of March 31, 2024.
• Cash and cash equivalents remained at $0 for both March 31, 2024, and December 31, 2023.
• Net cash used in operating activities increased to $(171,199) in Q1 2024 from $(92,775) in Q1 2023.
• The company raised $112,000 through convertible notes and $69,840 through promissory notes during Q1 2024.
• A settlement agreement was reached in the CSA 8411, LLC lawsuit for $125,000, expected to result in a gain on settlement of $53,526 upon full payment.
• A final judgment in the SEC lawsuit in July 2024 ordered the company to pay $520,940 in disgorgement, $59,295 in prejudgment interest, and a $100,000 civil penalty, totaling $680,235.

Sentiment

Score: 2

Explanation: The company faces severe liquidity issues, substantial doubt about its going concern ability, significant revenue declines, and ongoing legal and debt challenges. While net loss improved and some legal settlements are favorable, the overall financial health is precarious, and future operations are highly dependent on securing additional, uncertain financing.

Positives

• Net loss decreased by 27.95% to $(426,934) in Q1 2024 compared to $(592,560) in Q1 2023.
• Operating expenses, specifically selling, general and administrative, decreased by $65,814 or 16.61% due to reduced professional fees and a lack of bad debt expense from a related party in the current quarter.
• A gain of $21,420 was recognized on the settlement of debt and accrued expense in Q1 2024, compared to a loss of $350 in the prior year.
• A settlement agreement for $125,000 was reached in the CSA 8411, LLC lawsuit, resolving a $178,526 liability and potentially yielding a $53,526 gain on settlement.
• The company continues to develop its drug pipeline, including RPI78M which has Orphan Status from the FDA for pediatric Multiple Sclerosis, offering potential for shorter approval timelines and waived FDA fees.

Negatives

• Total net sales decreased significantly, with unrelated customer sales down 30.79% and related party sales (Avini Health) down 65.23%.
• Gross profit margin declined from 66.5% in Q1 2023 to 48.4% in Q1 2024, partly due to a $15,000 reserve for supplier advances.
• The company has an accumulated deficit of $75,372,408, a working capital deficit of $14,278,846, and a stockholders' deficit of $14,191,742 as of March 31, 2024.
• Net cash used in operating activities increased to $(171,199) in Q1 2024 from $(92,775) in Q1 2023, indicating a higher cash burn.
• The company's common stock is on the OTC Market Group's Expert Market, which limits its ability to raise capital.
• A final judgment in the SEC lawsuit ordered the company to pay $520,940 in disgorgement, $59,295 in prejudgment interest, and a $100,000 civil penalty, totaling $680,235.
• Many convertible notes and promissory notes are in default and under negotiation for settlement, indicating ongoing financial distress.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern due to recurring significant losses, accumulated deficit, and substantial indebtedness in default.
• The company does not have sufficient cash to sustain operations for the next twelve months and requires additional financing, which may not be available or could result in substantial dilution to existing shareholders.
• The significant decline in sales to Avini Health, a related party, is expected to reduce future revenues and may necessitate developing new customer relationships or product lines.
• The company faces intense competition in the biotechnology industry and risks negative impacts if it fails to compete effectively or execute planned partnering and out-licensing activities.
• Biotechnology industry-related litigation is substantial and may lead to increased costs and unpredictable outcomes.
• Failure to comply with extensive legal and regulatory requirements in the healthcare industry could result in increased costs, penalties, and business losses.
• The company's ability to conduct human clinical studies for its drug candidates is contingent on adequate financing, with no current timeline available.
• The company's common stock being on the OTC Market Group's Expert Market limits its ability to raise capital through traditional means.

Future Outlook

The company expects sales to Avini Health to decline significantly as Avini manufactures its own products, requiring the company to develop new customer relationships or product lines. It plans to re-engage in the regulatory approval process for Nyloxin in Canada in 2026 and aims to initiate Phase I/II trials for RPI78M in pediatric Multiple Sclerosis in 2026, contingent on adequate financing. The company estimates needing approximately $600,000 to fund existing operations over the next twelve months.

Management Comments

• "Our business during the three months ended March 31, 2024 has focused upon marketing our homeopathic drugs for the treatment of pain."
• "As sales increase, we plan to begin marketing more aggressively to increase the sales and awareness of our products."
• "Our goal is to initiate these trials [for RPI78M] in 2026."
• "As of the date of the filing of this report, we do not believe that our source of cash is adequate for the next 12 months of operation and there is substantial doubt about our ability to continue as a going concern."
• "We expect to utilize the proceeds from these funds and additional capital to manufacture Nyloxin and Pet PainAway and reduce our debt level."

Industry Context

The company operates in the biotechnology and over-the-counter pain relief markets. Its focus on non-opioid, non-NSAID pain relievers like Nyloxin aligns with growing consumer and regulatory concerns about opioid abuse and NSAID side effects. The development of RPI78M for Multiple Sclerosis, particularly with Orphan Status for pediatric MS, positions it in a high-need, specialized segment of the biologics market, potentially offering faster approval pathways. However, the company's limited funding and reliance on debt contrast sharply with the significant capital requirements typical for drug discovery and clinical trials in the biotech industry.

Comparison to Industry Standards

• The company's accumulated deficit of over $75 million and recurring significant losses are substantially worse than typical for a healthy, growing pharmaceutical or biotech company, which often require significant capital investment but aim for profitability or strong revenue growth.
• The reliance on related party sales, which are now significantly declining, indicates a lack of diversified revenue streams, a weakness compared to industry leaders with broad market penetration.
• The inability to fund clinical trials for RPI78M without additional financing, despite its Orphan Status, highlights a critical capital constraint that is atypical for biotech firms with promising drug candidates, which usually attract substantial investment.
• The company's stock being on the OTC Market Group's Expert Market is a significant disadvantage compared to publicly traded peers on major exchanges, limiting access to capital and investor visibility.
• The ongoing legal proceedings, including the SEC lawsuit and multiple debt defaults, suggest significant corporate governance and financial management issues that are far below industry best practices.

Management Changes

Corporate Governance

Legal Proceedings

• CSA 8411, LLC v. Nutra Pharma Corp.: A lawsuit filed on October 12, 2018, seeking to recover $100,000. A settlement agreement was reached on May 19, 2025, for $125,000, payable in installments, with a potential $400,000 consent judgment if default occurs.
• Securities and Exchange Commission v. Nutra Pharma Corporation, Erik Deitsch, and Sean Peter McManus: A lawsuit filed on September 28, 2018, alleging fraud and securities law violations. A final judgment was issued in July 2024, ordering the company to pay $520,940 in disgorgement, $59,295 in prejudgment interest, and a $100,000 civil penalty, totaling $680,235.

Related Party Transactions

• Net sales to Avini Health, a company owned by the former CEO, decreased by 65.23% to $34,949 in Q1 2024, as Avini began manufacturing its own products.
• The company sold certain equipment to Avini Health in 2023 for approximately $83,600, resulting in a gain of $39,700.
• The company relocated its operations to a Boca Raton facility leased by Avini, using the facility rent-free and sharing space and resources, with Avini paying all lease and office-related expenses.
• Convertible notes payable totaling $253,000 were reclassified to 'due to officer' upon Michael Flax's appointment as CEO/CFO in March 2024.
• The company owes its former director, Rik Deitsch, accrued interest of $173,772 as of March 31, 2024, on a defaulted loan from 2010.
• Accrued payroll due to officers increased to $1,416,790 as of March 31, 2024.
• Loans from officers totaled $124,529 and repayments were $45,823 during Q1 2024.

Stakeholder Impact

• Shareholders face significant dilution risk from potential future equity capital raises due to the company's liquidity issues and substantial doubt about its going concern ability.
• Shareholders are impacted by the company's stock being on the OTC Market Group's Expert Market, limiting trading liquidity and investor interest.
• Creditors, particularly holders of defaulted convertible notes and promissory notes, face uncertainty regarding repayment, with many notes in negotiation for settlement.
• Employees and management may face job insecurity or delayed compensation given the company's recurring losses and cash flow challenges, as evidenced by accrued payroll due to officers.
• Customers may experience potential disruptions if the company's financial instability impacts product availability or development of new offerings.

Next Steps

• Secure additional financing to fund operations and continue as a going concern.
• Increase ownership equity and attain profitable operations.
• Develop new customer relationships or product lines to offset declining sales to Avini Health.
• Re-engage in the regulatory approval process for Nyloxin in Canada, expected in 2026.
• Initiate human clinical studies for Nyloxin Extra Strength, contingent on adequate financing.
• Initiate Phase I/II trials for RPI78M in pediatric Multiple Sclerosis, targeted for 2026.
• Continue negotiations for settlement of various defaulted convertible notes and promissory notes.
• Make payments as per the CSA 8411, LLC settlement agreement (initial $35,000 on May 19, 2025, followed by nine monthly payments of $10,000).

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a substantial accumulated deficit, significant working capital and stockholders' deficits, and zero cash. The 'going concern' warning is explicit and well-founded. While the net loss decreased, this was largely offset by a drastic decline in revenue, particularly from a key related party. The company's reliance on continuous debt financing, much of which is in default, and the potential for massive shareholder dilution from future capital raises, present an extremely high-risk profile. The SEC lawsuit's final judgment adds a substantial financial burden. The stock's placement on the OTC Expert Market further limits liquidity and investor appeal. Given the precarious financial position, operational challenges, and ongoing legal and debt issues, the stock represents a strong sell for any investor.

Keywords

Biotechnology, Pharmaceuticals, Pain relief, SEC filing, Going concern, Net loss, Convertible debt, Liquidity, OTC Market, Drug development, Orphan status, Litigation